Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
03 02 2020
Historique:
received: 18 12 2019
accepted: 27 01 2020
entrez: 5 2 2020
pubmed: 6 2 2020
medline: 29 12 2020
Statut: epublish

Résumé

Glioblastoma is the most frequent and aggressive primary brain tumor, characterized by extensive brain invasion and rarely, systemic metastases. The pathogenesis of metastatic glioblastoma is largely unknown. We present the first integrated clinical/histologic/genetic analysis of 5 distinct brain and lung foci from a unique case of recurrent, multifocal, multicentric and metastatic glioblastoma. The initial right frontotemporal gliosarcoma received standard surgical/chemoradiation therapy and recurred 1.5 years later, co-occurring with three additional masses localized to the ipsilateral temporal lobe, cerebellum and lung. Synchronous metastatic lung carcinoma was suspected in this long-term smoker patient with family history of cancer. However, glioblastoma was confirmed in all tumors, although with different morphologic patterns, including ependymomatous and epithelioid. Genomic profiling revealed a germline FANCD2 variant of unknown significance, and a 4-gene somatic mutation signature shared by all tumors, consisting of TERT promoter and PTEN, RB1 and TP53 tumor suppressor mutations. Additional GRIN2A and ATM heterozygous mutations were selected in the cerebellar and lung foci, but were variably present in the supratentorial foci, indicating reduced post-therapeutic genetic evolution in brain foci despite morphologic variability. Significant genetic drift characterized the lung metastasis, likely explaining the known resistance of circulating glioblastoma cells to systemic seeding. MET overexpression was detected in the initial gliosarcoma and lung metastasis, possibly contributing to invasiveness. This comprehensive analysis sheds light on the temporospatial evolution of glioblastoma and underscores the importance of genetic testing for diagnosis and personalized therapy.

Identifiants

pubmed: 32014051
doi: 10.1186/s40478-020-0889-x
pii: 10.1186/s40478-020-0889-x
pmc: PMC6998196
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10

Subventions

Organisme : NeuroMarkers PLLC
ID : NM2019-03
Pays : International

Références

J Neurooncol. 2011 Nov;105(2):261-73
pubmed: 21512826
Oncotarget. 2019 Jun 18;10(40):4038-4052
pubmed: 31258848
Neoplasia. 2010 Jun;12(6):453-63
pubmed: 20563248
Cancers (Basel). 2011 Jan 27;3(1):461-77
pubmed: 24212625
Int J Cancer. 2002 Jul 10;100(2):131-5
pubmed: 12115559
Sci Transl Med. 2014 Jul 30;6(247):247ra101
pubmed: 25080476
Case Rep Oncol. 2018 Aug 28;11(2):591-600
pubmed: 30283316
Cancer Cell. 2003 Apr;3(4):347-61
pubmed: 12726861
J Invest Dermatol. 2014 Sep;134(9):2390-2398
pubmed: 24739903
Acta Neuropathol Commun. 2015 Mar 08;3:11
pubmed: 25775275
Acta Neuropathol Commun. 2015 Dec 04;3:81
pubmed: 26637293
Mol Cell Biol. 2007 Apr;27(7):2527-37
pubmed: 17242191
Acta Neuropathol. 2017 Feb;133(2):263-282
pubmed: 28074274
Int J Cancer. 2007 Jul 15;121(2):276-83
pubmed: 17372907
Am J Pathol. 2000 Feb;156(2):425-32
pubmed: 10666371
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182-7
pubmed: 10468583
J Neuropathol Exp Neurol. 2000 Dec;59(12):1044-50
pubmed: 11138924
Cell Cycle. 2016;15(8):1134-43
pubmed: 27097374
Science. 2011 Jul 15;333(6040):312-6
pubmed: 21764741
J Mol Med (Berl). 2007 May;85(5):497-509
pubmed: 17221219
World Neurosurg. 2018 Apr;112:e74-e83
pubmed: 29258946
Neoplasia. 2010 Dec;12(12):1013-22
pubmed: 21170265
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Am J Surg Pathol. 2013 May;37(5):685-98
pubmed: 23552385
Int J Mol Sci. 2017 Aug 19;18(8):null
pubmed: 28825622
J Invest Dermatol. 2014 Oct;134(10):2630-2638
pubmed: 24662767
Genes Cancer. 2010 Dec;1(12):1170-7
pubmed: 21779440
Acta Neuropathol Commun. 2016 May 27;4(1):55
pubmed: 27229317
Genes Chromosomes Cancer. 2014 Jul;53(7):589-605
pubmed: 24706357
Oncotarget. 2018 Jun 19;9(47):28652-28665
pubmed: 29983887
Cancers (Basel). 2017 Apr 17;9(4):null
pubmed: 28420162
Cell Cycle. 2014;13(19):2999-3015
pubmed: 25486561
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
J Neurooncol. 2007 May;83(1):39-46
pubmed: 17171442

Auteurs

Maria-Magdalena Georgescu (MM)

NeuroMarkers PLLC, Houston, TX, 77025, USA. mmgeorgescu@yahoo.com.

Adriana Olar (A)

Department of Pathology and Neurosurgery, Medical University of South Carolina and Hollings Cancer Center, Charleston, SC, 29425, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH